Study Endpoints
toxicities, tumor, DLT
DISEASE, BONE METASTASES, TUMOR
The primary endpoint of the overall study was objective response rate (ORR) in patients treated at the RP2D of pembrolizumab and cabozantinib. Secondary endpoints included dose-limiting toxicities (DLT), MTD, disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of treatment, time to response, and duration of response (DoR). Exploratory endpoints included PD-L1 status of archival tumor samples and serum bone turnover markers in patients with bone metastases.